Newswire (Published: Tuesday, April 11, 2017, 5:00:00 AM CDT, Received: Tuesday, April 11, 2017, 5:00:11 AM CDT)
Word Count: 1146
Through its systematic review of the evidence, the
The draft recommendation applies to adult men who have not been previously diagnosed with prostate cancer and have no signs or symptoms of the disease. The draft recommendation applies to men at average risk and men who are at increased risk for prostate cancer, such as
Draft Recommendation by Age:
55–69: Recommends informed,
70 and older: Not recommended.
The PSA test measures the amount of prostate-specific antigen, a type of protein, in a man's blood. When a man has an elevated PSA, it may be caused by prostate cancer, but it could also be caused by other conditions, such as an enlarged prostate or an inflammation of the prostate. PSA-based screening and follow-up prostate biopsies cannot tell for sure which cancers are likely to be aggressive and spread, and which will not—or will grow so slowly that they will never cause symptoms. Because there is no good way to distinguish men who will have high-risk cancers from those who won't, most men receive surgery or radiation to treat prostate cancer, including many men who do not benefit at all. It's important for men who are considering screening to understand that screening has both potential benefits and harms.
The Task Force reviewed new evidence that increases confidence in the benefits of screening, which includes reducing the chance of dying from prostate cancer. Another important benefit of screening is reducing the risk of metastatic cancer. Metastatic cancer is the spread of cancer cells to new areas of the body. Because prostate cancer often grows slowly, the benefits of screening are generally realized years, even more than a decade, after diagnosis and treatment. The potential harms from screening and treatment, however, may occur immediately. The harms of screening include frequent false-positive results, which often lead to immediate, additional testing and years of additional close follow-up, including repeated blood tests and biopsies. The harms associated with treatment commonly include sexual impotence and urinary incontinence. Many more men are expected to experience the harms of screening and treatment than will experience benefit.
"Prostate cancer is one of the most common cancers to affect men, and the decision about whether to begin screening using PSA-based testing is complex. For men who are more willing to accept the potential harms, screening may be the right choice for them. Men who are more interested in avoiding the potential harms may choose not to be screened," says
The draft recommendation is also based in part on new evidence on the use of active surveillance, which includes regular, repeated PSA testing and often repeated digital rectal examination and prostate biopsy. Active surveillance has become a more common treatment choice for men with lower-risk prostate cancer over the past several years, and may reduce the chance of overtreatment. It may also offer men the opportunity to delay active treatment and complications—or avoid active treatment completely.
"Clinicians should speak with their
The Task Force also recommends that clinicians talk with patients who have a family history of prostate cancer, particularly those with a father or brother diagnosed with prostate cancer, about their increased risk of developing the disease. The Task Force calls for more research on the potential benefits and harms of screening for prostate cancer among men with a family history of prostate cancer.
The Task Force's draft recommendation statement and draft evidence reviews have been posted for public comment on the
The Task Force is an independent, volunteer panel of national experts in prevention and evidence-based medicine that works to improve the health of all Americans by making evidence-based recommendations about clinical preventive services such as screenings, counseling services, and preventive medications.
Contact: USPSTF Media Coordinator at Newsroom@USPSTF.net / (202) 572-2044
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/us-preventive-services-task-force-seeks-comments-on-draft-recommendation-statement-on-screening-for-prostate-cancer-300437870.html